Karkhaneh Leyla, Tabatabaei-Malazy Ozra, Bandarian Fatemeh, Mohseni Shahrzad, Larijani Bagher
Personalized Medicine Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Physiology Department, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
J Diabetes Metab Disord. 2021 Dec 1;21(1):863-879. doi: 10.1007/s40200-021-00908-x. eCollection 2022 Jun.
Genetic factors have a role in response to a target medication (personalized medicine). This study aimed to review available evidence about the relationship between gene variants and therapeutic response to sulfonylureas in type 2 diabetes, systematically.
An extensive search was done in Scopus, PubMed, and Web of Science with specific search strategy in the field from the beginning until the 1 of Jan. 2021. After sending records to endnote software and removing duplicate records remained documents were screened by title and abstract. Full texts of remained documents were assessed after removing un-related records. Required data was extracted from remained documents and records were categorized according to gene/SNP studied.
Finally, 26 studies with 9170 T2DM patients with a mean age of 59.47 ± 6.67 (49.7-75.2 years) remained. The most contribution was from China, Slovakia and Greece, respectively and the most genes studied were , and both and with 10, 7, and 4 articles, respectively. Also, rs1799853 and rs1057910 (each with seven studies), rs5219 with six studies and (with four articles), respectively were the most common variants investigated. Studies about each gene obtained different positive or negative results and were not consistent.
Considering heterogeneity between SFUs pharmacogenomic studies regarding the method, sample size, population, gene/variant studied, and outcome and findings, these studies are not conclusive and need further studies.
遗传因素在对靶向药物的反应（个性化医疗）中起作用。本研究旨在系统回顾有关2型糖尿病中基因变异与磺脲类药物治疗反应之间关系的现有证据。
在Scopus、PubMed和Web of Science中进行了广泛检索，采用该领域特定的检索策略，检索时间从开始至2021年1月1日。将记录导入EndNote软件并去除重复记录后，通过标题和摘要对剩余文献进行筛选。去除无关记录后，对剩余文献的全文进行评估。从剩余文献中提取所需数据，并根据所研究的基因/单核苷酸多态性（SNP）对记录进行分类。
最终，保留了26项研究，涉及9170例2型糖尿病患者，平均年龄为59.47±6.67岁（49.7 - 75.2岁）。贡献最大的分别是中国、斯洛伐克和希腊，研究最多的基因分别是 、 以及 和 ，分别有10篇、7篇和4篇文章。此外，rs1799853和rs1057910（各有7项研究）、rs5219有6项研究以及 （有4篇文章）分别是研究最多的常见变异。关于每个基因的研究得出了不同的阳性或阴性结果，且并不一致。
考虑到磺脲类药物药物基因组学研究在方法、样本量、人群、所研究的基因/变异以及结果和发现方面存在异质性，这些研究尚无定论，需要进一步研究。
